ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Hitoshi Kasegawa
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kohno, H.
Right arrow Articles by Miyazaki, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohno, H.
Right arrow Articles by Miyazaki, M.
Related Collections
Right arrow Electrophysiology - arrhythmias

Ann Thorac Surg 2005;79:117-126
© 2005 The Society of Thoracic Surgeons

Original article: Cardiovascular

Three-Day Magnesium Administration Prevents Atrial Fibrillation After Coronary Artery Bypass Grafting

Hiroki Kohno, MDa,b,*, Toshiya Koyanagi, MDa, Hitoshi Kasegawa, MDa, Masaru Miyazaki, MDb

a Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo
b Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan

Accepted for publication June 16, 2004.

* Address reprint requests to Dr Kohno, Department of General Surgery, Graduate School of Medicine, Chiba University, 1–8–1 Inohana, Chuo-ku, 260–8670 Chiba, Japan (E-mail: hkcw{at}mac.com).

BACKGROUND: The efficacy of magnesium administration in preventing the occurrence of atrial fibrillation after coronary artery bypass grafting surgery remains controversial. Optimal dose and timing of the administration also await clarification. The purpose of this study was to assess the effect of 3-day postoperative infusion of magnesium on postoperative atrial fibrillation and to find factors that can influence the efficacy of this treatment.

METHODS: After institutional review board approval, a retrospective study was conducted reviewing 200 consecutive patients who underwent isolated, initial coronary artery bypass grafting operation. The first 100 patients did not receive the prophylactic treatment, whereas the next 100 patients were treated with magnesium postoperatively. Patients in the magnesium-treated group received 10 mmol (2.47 g) of magnesium sulfate (MgSO4 · 7H2O) infused daily for 3 days after surgery.

RESULTS: The incidence of postoperative atrial fibrillation was 35% in the untreated group compared with 16% in the magnesium-treated group (p = 0.002). Multivariate logistic regression analysis revealed that advanced age, decreased left ventricular ejection fraction, and absence of magnesium therapy were independent predictors of postoperative atrial fibrillation. For patients receiving the magnesium therapy, advanced age and decreased ejection fraction were the independent factors that predicted the arrhythmia.

CONCLUSIONS: Postoperative 3-day magnesium infusion is effective in reducing the incidence of atrial fibrillation occurring after coronary artery bypass grafting surgery. However, in older patients or in patients with reduced left ventricular function, magnesium treatment alone is insufficient for prophylaxis of postoperative atrial fibrillation.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. M. Manrique, M. Arroyo, Y. Lin, S. R. El Khoudary, E. Colvin, S. Lichtenstein, C. Chrysostomou, R. Orr, E. Jooste, P. Davis, et al.
Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study
J. Thorac. Cardiovasc. Surg., January 1, 2010; 139(1): 162 - 169.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
M. A. Vos
Enhanced efficacy with MgSO4 due to an additive, alternative, or dual mode of action?
Europace, July 1, 2009; 11(7): 844 - 845.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. Guler, C. Ozkara, H. Dulger, V. Kutay, M. Sahin, E. Erbilen, and H. A. Gumrukcuoglu
Do Cardiac Neuropeptides Play a Role in the Occurrence of Atrial Fibrillation After Coronary Bypass Surgery?
Ann. Thorac. Surg., February 1, 2007; 83(2): 532 - 537.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.